2016 American Transplant Congress
Urine IP-10 as the Biomarker for ABMR in Kidney Transplant Recipient with DGF.
Background: In the setting of DGF in kidney transplantation (KT), early acute ABMR, which needs early treatment, has to be differentiated from simple ischemic acute…2016 American Transplant Congress
Glomerular Capillary C4d Staining without Evidence of Rejection Is Associated with Worse Graft Function in ABO-Incompatible Kidney Transplantation.
Objectives: C4d staining in the peritubular capillaries (C4d-PTC) is often observed without evidence of rejection in ABO-incompatible kidney transplantation (ABOI-KTx), and this phenomenon is generally…2016 American Transplant Congress
Association of Genetic Polymorphisms in Complement Independent Pathways with Donor Specific Antibodies in Kidney Allograft Recipients.
Background: It is known that detection of donor specific antibodies (DSA) is associated with antibody mediated rejection (AMR) and poor allograft outcomes. DSA mediates graft…2016 American Transplant Congress
The Coefficient of Variability of Tacrolimus Levels Can Predict Antibody-Mediated Rejection After Renal Transplantation.
Introduction. Antibody-mediated rejection (ABMR) is the major cause of allograft failure. We studied whether the coefficient of variability (CV) of blood levels of tacrolimus can…2016 American Transplant Congress
IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.
Introduction Transplant glomerulopathy (TG) is commonly associated with chronic antibody mediated rejection and is a major cause of late kidney allograft loss with no established…2016 American Transplant Congress
Breadth of HLA-Specific B Cell Reactivity and Frequency Assessed by a Novel Multiplex Bead Based Assay Predicts and Correlates with Rejection in Kidney Transplant Recipients.
Northwestern University, Chicago.
Introduction: Recipients with broad sensitization to HLA defined by a high percentage of Panel Reactive Antibodies (PRA) are at higher immunologic risk for poor graft…2016 American Transplant Congress
Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer.
Induction therapies are commonly used during kidney transplantation (~85% of transplants in 2012). Existing studies of induction therapy are limited by short follow-up and/or absence…2016 American Transplant Congress
Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.
Antithymocyte globulin (ATG) is recommended over IL-2 receptor antagonist (IL2) in high-risk recipients for induction immunosuppression. However, “high-risk” status has not been defined in an…2016 American Transplant Congress
Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.
UC San Diego Health System, San Diego, CA.
Background: Rabbit anti-thymocyte globulin (rATG) is a depleting polyclonal antibody often used for induction following kidney transplantation to help prevent acute rejection. The optimal dosage…2016 American Transplant Congress
Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients.
Background: In descriptive studies, alemtuzumab has been associated with an escalating risk of death and graft loss in elderly (≥65 years) kidney transplant recipients. However,…
American Transplant Congress abstracts